Semelil (ANGIPARSTM)	Placebo	Baseline characteristics (except cholesterol levels)	10974	11106	There were not significant differences between two groups at the baseline in demographic profile with exception of cholesterol value
Semelil (ANGIPARSTM)	Placebo	Michigan diabetic neuropathy score	1005	1082	Michigan diabetic neuropathy score was decreased notably in ANGIPARSTM group.
Semelil (ANGIPARSTM)	Placebo	Michigan diabetic neuropathy score	-1	-1	<td align="left" colspan="1" rowspan="1"></td><td align="left" colspan="1" rowspan="1"></td><td align="center" colspan="1" rowspan="1"></td><td align="center" colspan="1" rowspan="1">0</td><td align="center" colspan="1" rowspan="1">2</td>
Semelil (ANGIPARSTM)	Placebo	Adverse events	16370	16458	In this study significant adverse effect was not observed by the laboratory evaluations.
Semelil (ANGIPARSTM)	Placebo	Michigan diabetic neuropathy score	-1	-1	<td align="left" colspan="1" rowspan="1">Michigan neuropathy score</td><td align="center" colspan="1" rowspan="1">4.9±4.5</td><td align="center" colspan="1" rowspan="1">4.3±4.5</td><td align="center" colspan="1" rowspan="1">0.19</td><td align="center" colspan="1" rowspan="1">4.1±3</td><td align="center" colspan="1" rowspan="1">2.8±2.9</td><td align="center" colspan="1" rowspan="1">0.002</td><td align="center" colspan="1" rowspan="1">0.44</td>
